Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1992-3-30
|
| pubmed:abstractText |
The present study provides immunobiochemical and molecular data on the differentiation-linked expression of the bcl-2 proto-oncogene in normal and neoplastic myeloid cells. Using a recently developed monoclonal antibody (MoAb) to the bcl-2 molecule, staining of normal bone marrow myeloblasts, promyelocytes, and myelocytes, but neither monocytes nor most polymorphonuclear cells, was demonstrated. By two-color flow cytometric analysis, bcl-2 was evidenced in CD33+ and CD33+/CD34+ myeloid cells as well as in the more primitive CD33-/CD34+ population. The leukemic cell lines HL-60, KG1, GM-1, and K562 were bcl-2 positive together with 11 of 14 acute myeloid leukemias (AML) and three of three chronic myeloid leukemias (CML) in blast crises; six of seven CML were negative. Among myelodysplastic cases, augmentation of the bcl-2 positive myeloblastic compartment was found in refractory anemia with excess of blasts (RAEB) and in transformation (RAEB-t). Western blots of myeloid leukemias and control lymphocytes extracts evidenced an anti-bcl-2 immunoreactive band of the expected size (26 Kd). Moreover, the HL-60 and KG1 cell lines, both positive for the bcl-2 protein, exhibited the appropriate size bcl-2 mRNA (7.5 Kb). These findings clearly indicate that the bcl-2 gene is operative in myeloid cells and that the anti-bcl-2 MoAb identifies its product and not a cross-reactive epitope. Induction of HL-60 differentiation toward the monocytic and granulocytic pathways was accompanied by a marked decrease in bcl-2 mRNA and protein levels; bivariate flow cytometric analysis showed that the fraction becoming bcl-2 negative was in the G1 phase of the cell cycle. These data establish that the bcl-2 proto-oncogene is expressed on myeloid cells and their progenitors and is regulated in a differentiation-linked manner.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
79
|
| pubmed:geneSymbol |
bcl-2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1291-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1536952-Anemia, Refractory, with Excess of Blasts,
pubmed-meshheading:1536952-Blotting, Western,
pubmed-meshheading:1536952-Bone Marrow,
pubmed-meshheading:1536952-Cell Differentiation,
pubmed-meshheading:1536952-Flow Cytometry,
pubmed-meshheading:1536952-Gene Expression,
pubmed-meshheading:1536952-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:1536952-Granulocytes,
pubmed-meshheading:1536952-Humans,
pubmed-meshheading:1536952-Immunohistochemistry,
pubmed-meshheading:1536952-Leukemia,
pubmed-meshheading:1536952-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:1536952-Leukemia, Myeloid, Acute,
pubmed-meshheading:1536952-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:1536952-Proto-Oncogene Proteins,
pubmed-meshheading:1536952-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:1536952-RNA, Messenger,
pubmed-meshheading:1536952-Tumor Cells, Cultured
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.
|
| pubmed:affiliation |
Istituto Nazionale per Lo Studio e La Cura Dei Tumori, Milan, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|